Similarly, the increased expression of PRDX2 was remarkably associated with progression-free survival (PFS) (P < 0.0001), in 982 patients with lung cancer (491 samples with low PRDX2 expression and 491 samples with high PRDX2 expression) (Figure 1(b)). This evidence concerns the gene PRDX2 and lung carcinoma.